<DOC>
	<DOCNO>NCT03090932</DOCNO>
	<brief_summary>Amyotrophic lateral sclerosis ( ALS ) devastate neurodegenerative disorder characterize progressive muscle weakness eventual death . Studies demonstrate immune system play key role ALS progression ; however , role immune system unclear , various aspect play beneficial detrimental role disease course . Attempts universally suppress immune system ALS patient best negligible effect progression worst accelerate disease . Thus , critical need identify immune cell population serve biomarkers therapeutic target .</brief_summary>
	<brief_title>Longitudinal Study Innate Lymphoid Cells Peripheral Blood ALS</brief_title>
	<detailed_description>Application - HUM00107546 Study Title : Longitudinal Study Innate Lymphoid Cells Peripheral Blood ALS Full Study Title : Longitudinal Study Innate Lymphoid Cells Peripheral Blood ALS If U-M study relate project , enter eResearch ID number ( HUM # ) IRBMED Legacy study number . Examples related project include , limited : 00028826 - Epidemological Risk Factors The Genetics ALS Principal Investigator : - Benjamin Murdock , PhD Study Team Members : - Eva Feldman , MD , PhD Co-Investigator - Stephen Goutman , MD Co-Investigator - Ximena Paez-Colasante , PhD Post-Doctoral Fellow - Crystal Pacut , Biorepository Coordinator - Jayna Duell , Study Coordinator - Blake Swihart , Study Coordinator - Benjamin Segal , MD Consultant - Meeyoung Park , Biostatistician Project Summary : Amyotrophic lateral sclerosis ( ALS ) devastate neurodegenerative disorder characterize progressive muscle weakness eventual death . Studies demonstrate immune system play key role ALS progression ; however , role immune system unclear , various aspect play beneficial detrimental role disease course . Attempts universally suppress immune system ALS patient best negligible effect progression worst accelerate disease . Alternatively , augment deplete specific immune cell population ALS mouse model alters disease course slow progression . Thus , critical need identify immune cell population serve biomarkers therapeutic target . Neuroinflammation hallmark ALS human patient mouse model . While clinical symptom result motor neuron degeneration , become increasingly clear immune system play key role pathology . A variety insult give rise identical immune response go produce characteristic clinical histopathological manifestation motor neuron disease . This make immune system attractive target therapeutic , wide variety potential ALS source funnel common immunological pathway course disease . The investigator recent study demonstrate ALS patient increase level several subpopulation innate lymphoid cell ( ILCs ) peripheral blood . A subset patient ILC level 5-10 time great find healthy control patient . The difference see ILC level peripheral blood much great difference see immune cell population ALS . Thus , cell population attractive candidate use biomarkers therapeutic target . The propose study break three broad phase applicable patient : recruitment , sample collection , analysis . Following diagnosis disease , ALS patient live within 1 hour University Michigan call clinical coordinator enrol study ( recruitment ) . Following enrollment study , patient visit every 28 Â± 3 day year initial visit Michigan Institute Clinical &amp; Health Research ( MICHR ) clinical research unit ; unit take 10 ml blood per patient . Samples return University Michigan . ILCs isolate peripheral blood use fluorescence-activated cell sort ( FACS ) mRNA ILC population collect cytokine production analyze use multiplex ( analysis ) . On day collection , clinician clinical coordinator University Michigan Comprehensive ALS Clinic ( UMCAC ) contact patient complete ALSFRS-R questionnaire ass physical deterioration patient . The study also incorporate control subject . The control subject blood take month 12 month , complete ALSFRS-R questionnaire diagnose ALS therefore questionnaire fit . 10ml blood take per visit .</detailed_description>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>Age 18 year old . Fluency English 6th grade level higher . Able communicate sufficiently well speak Able communicate phone . Capable provide informed consent . Lives within 1 hour University Michigan Definite , probable , possible ALS diagnosis Unable provide inform consent . Clinically significant dementia , judge site investigator . Other neurological psychiatric disorder expect impair cognitive function . Other serious uncontrolled medical disorder . History autoimmune disease . Use prednisone , IVIG , immunosuppression within last 12 month . Lives 1 hour University Michigan</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>